SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Core Insights - Aquestive Therapeutics, Inc. experienced a significant stock decline of approximately 40% intraday following the disclosure of deficiencies identified by the U.S. Food and Drug Administration (FDA) in its New Drug Application (NDA) for Anaphylm, an experimental treatment for severe allergic reactions [5] Group 1 - The FDA's identification of deficiencies prevents discussions regarding labeling and post-marketing requirements, raising concerns about the approvability of the NDA ahead of the January 31, 2026, PDUFA action date [5] - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics for investors who suffered significant losses [2][4]